Sector: Healthcare | Industry: Pharmaceuticals |
Company Contact | |
Address: | 595 Burrard Street, Suite 2600 VANCOUVER BC V7X 1L3 |
Tel: | N/A |
Website: | https://www.aequuspharma.ca |
IR: | See website |
Key People | ||
Douglas Glen Janzen Chairman of the Board, President, Chief Executive Officer | Ann Fehr Chief Financial Officer, Corporate Secretary | Grant Larsen Chief Commercial Officer |
Business Overview |
Aequus Pharmaceuticals Inc. is a Canada-based specialty pharmaceutical company focused on developing, advancing, and promoting differentiated products. The Company is engaged in the sale and marketing of several commercial products in ophthalmology and transplant. Its pipeline products include Evolve Intensive Gel, Evolve Daily Intensive, SCOPE Portfolio, Zimed PF and REV-0100 / ReVision. Evolve Intensive Gel and Evolve Daily Intensive contains lubricating eye drops intended for use in the relief of discomfort that arises from dry eye sensations, including dryness, soreness, feelings of grit, and irritation. Zimed PF is a preservative-free multi-dose Bimatoprost for glaucoma patients in Canada. REV-0100 is in preclinical development as a treatment for Stargardt disease. It plans to build on its Canadian commercial platform through the launch of additional products that are either created internally or brought in through an acquisition or license. |
Financial Overview |
For the nine months ended 30 September 2023, Aequus Pharmaceuticals Inc revenues decreased 80% to C$204K. Net loss increased 3% to C$2.2M. Revenues reflect Promotional services segment decrease from C$827K to C$0K, Canada segment decrease of 68% to C$112K. Higher net loss reflects Canada segment loss increase of 90% to C$1.5M. Basic Earnings per Share excluding Extraordinary Items remained flat at -C$0.02. |
Employees: | 12 as of Dec 31, 2022 |
Reporting Currency: | Canadian Dollars |
Enterprise value: | $4.48M as of Sep 30, 2023 |
Annual revenue (TTM): | $0.59M as of Sep 30, 2023 |
EBITDA (TTM): | -$2.44M as of Sep 30, 2023 |
Net annual income (TTM): | -$3.27M as of Sep 30, 2023 |
Free cash flow (TTM): | -$1.84M as of Sep 30, 2023 |
Net Debt Last Fiscal Year: | $3.93M as of Sep 30, 2023 |
Shares outstanding: | 132,634,431 as of Sep 30, 2023 |
TTM: Trailing Twelve Months EBITDA: Earnings Before Interest, Taxes, Depreciation, & Amortization |